|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||35.62 - 37.18|
|52 Week Range||34.85 - 70.82|
|Beta (5Y Monthly)||1.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||56.80|
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 29, 2021, the company approved non-statutory stock options to purchase an aggregate of 83,750 shares of its common stock and 21,550 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 49 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30 at 8:25 a.m. ET.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...